Clinical Trial

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.
Trial Details
NCT Number NCT06585761
Lead Sponsor Kafrelsheikh University
Conditions Heart Failure
Enrollment 60 participants
Start Date 2024-02-15
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-05